Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership reduced its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 2.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,906,790 shares of the company's stock after selling 53,680 shares during the period. Artisan Partners Limited Partnership owned about 1.25% of Wave Life Sciences worth $23,587,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of WVE. Intech Investment Management LLC purchased a new stake in Wave Life Sciences in the 3rd quarter valued at about $194,000. Charles Schwab Investment Management Inc. grew its stake in Wave Life Sciences by 209.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company's stock worth $6,926,000 after purchasing an additional 571,345 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Wave Life Sciences by 20.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 168,141 shares of the company's stock worth $1,379,000 after purchasing an additional 28,351 shares during the period. FMR LLC raised its position in Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company's stock valued at $12,630,000 after purchasing an additional 979,110 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Wave Life Sciences by 477.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 41,828 shares of the company's stock worth $343,000 after buying an additional 34,588 shares during the period. Hedge funds and other institutional investors own 89.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on WVE shares. Jefferies Financial Group initiated coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a "buy" rating and a $26.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, March 26th. Finally, StockNews.com upgraded shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $22.60.

Insider Buying and Selling at Wave Life Sciences

In related news, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares of the company's stock, valued at $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Stock Up 1.9 %

Shares of Wave Life Sciences stock traded up $0.15 during trading on Wednesday, reaching $7.89. The company's stock had a trading volume of 508,960 shares, compared to its average volume of 1,134,526. The company has a 50-day simple moving average of $10.61 and a two-hundred day simple moving average of $11.75. Wave Life Sciences Ltd. has a 1-year low of $4.25 and a 1-year high of $16.74. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -7.08 and a beta of -0.93.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. As a group, analysts anticipate that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.